Redhill Biopharma Ltd. American Depositary Shares (RDHL)
Stock · NASDAQ · Health Care
$0.48as of 10/16/2026
Price chart
Active signals
RDHL Signal Track Record
How signals performed across all stocks →What RDHL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 33 | -7.3% | 36% | October 8, 2026 |
| Bollinger Band Breakdown | 25 | -12.3% | 20% | August 6, 2026 |
| Bollinger Band Breakout | 17 | -17.4% | 24% | August 28, 2026 |
| Any 20-session window (baseline) | -11.9% | 29% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RDHL
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hos…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 13
- Website
- www.redhillbio.com/
Fundamentals
- 1-day range
- $0.48$0.51
- Market cap
- $3.53M
- P/E (trailing)
- Infinity
- P/E (forward)
- 16.00
- EPS (trailing)
- $-0.00
- Dividend yield
- —
- Beta
- 4.97
- Avg. volume
- 2.06M
Redhill Biopharma Ltd. American Depositary Shares Competitors
Chosen by industry and closest market cap.
- RDHLRedhill Biopharma Ltd. American Depositary Shares$0.48▼ 3.81%Market cap $3.53MP/E Infinity$0.4351$2.14
- XRTXXORTX Therapeutics Inc. Common Shares$1.24▼ 12.68%Market cap $3.51MP/E —$2.42$9.85
- PRFXPRF Technologies Ltd. Ordinary Shares$0.781▼ 7.68%Market cap $3.35MP/E —$0.8099$7.95
- ONCOOnconetix Inc. Common Stock$0.479▼ 12.59%Market cap $3.34MP/E 0.00$0.535$200
- SXTP60 Degrees Pharmaceuticals Inc. Common Stock$0.855▼ 4.89%Market cap $3.28MP/E —$0.835$8.62
- SPRCSciSparc Ltd. Ordinary Shares$1.7▼ 15.00%Market cap $3.85MP/E —$1.63$43.65
- MBIOMustang Bio Inc. Common Stock$0.376▼ 2.59%Market cap $3.87MP/E —$0.3701$1.69
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RDHL Redhill Biopharma Ltd. American Depositary Shares | $3.53M | Infinity | $0.48 | ▼ 3.81% | $0.4351$2.14 |
| XRTX XORTX Therapeutics Inc. Common Shares | $3.51M | — | $1.24 | ▼ 12.68% | $2.42$9.85 |
| PRFX PRF Technologies Ltd. Ordinary Shares | $3.35M | — | $0.781 | ▼ 7.68% | $0.8099$7.95 |
| ONCO Onconetix Inc. Common Stock | $3.34M | 0.00 | $0.479 | ▼ 12.59% | $0.535$200 |
| SXTP 60 Degrees Pharmaceuticals Inc. Common Stock | $3.28M | — | $0.855 | ▼ 4.89% | $0.835$8.62 |
| SPRC SciSparc Ltd. Ordinary Shares | $3.85M | — | $1.7 | ▼ 15.00% | $1.63$43.65 |
| MBIO Mustang Bio Inc. Common Stock | $3.87M | — | $0.376 | ▼ 2.59% | $0.3701$1.69 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher Into Earnings GauntletYahoo · 10/1/2026
- Redhill Biopharma H1 2026 EPS $0.00 And Revenue $0.00benzinga · 9/30/2026
- RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial ResultsYahoo · 9/30/2026
- Redhill Biopharma H1 2026 EPS $0.00 And Revenue $0.00Benzinga · 9/30/2026
Insider Activity
Insider Actions →- Gilead Raday · October 1, 2026 · Option Exercise27.56M
- Gilead Raday · October 1, 2026 · Sale14.31M @ $0.0001
- Gilead Raday · July 10, 2026 · Option Exercise28.15M
- Gilead Raday · July 10, 2026 · Sale14.13M @ $0.0001
Institutional Ownership
March 31, 2026
- Total shares held
- 518.7K
- Total value held
- $386.5K
- Institutional holders
- 16
- Unknown350.9K
- Unknown88.4K
- Unknown20.7K
- Unknown15.2K
- Unknown14.5K
- Unknown13.0K
- Unknown6.7K
- Unknown5.1K
- Unknown3.4K
- Unknown826
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
RedHill Biopharma reports zero revenue and EPS for H1 2026
RedHill Biopharma announced its first half 2026 financial results, reporting zero revenue and zero earnings per share. The company also shared operational highlights alongside these figures. This report provides a snapshot of the company's current financial position, noting that it generated no income during this period.
RedHill Biopharma reports zero revenue and EPS for H1 2026. RedHill Biopharma announced its first half 2026 financial results, reporting zero revenue and zero earnings per share. The company also shared operational highlights alongside these figures. This report provides a snapshot of the company's current financial position, noting that it generated no income during this period.